Circovirus sequences associated with piglet weight loss disease (PWD)
View Patent ↗The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection is further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.
1. A vector capable of expressing at least one polypeptide encoded by a nucleic acid sequence comprising a sequence having at least 90% sequence identity to SEQ. ID. NO: 25.
2. The vector of claim 1 , wherein the vector is a baculovirus vector.
3. A vector capable of expressing at least one polypeptide encoded by a nucleic acid sequence comprising a sequence having at least 95% sequence identity to SEQ. ID. NO: 25.
4. The vector of claim 3 , wherein the vector is a baculovirus vector.
5. A vaccine composition, comprising the vector of claim 1 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
6. A vaccine composition, comprising the vector of claim 2 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
7. A vaccine composition, comprising the vector of claim 3 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
8. A vaccine composition, comprising the vector of claim 4 and a pharmaceutically or veterinarily acceptable carrier, wherein said nucleic acid sequence encodes an immunogenic protein that induces a protective response effective against infection by a piglet weight loss disease virus.
9. An immunogenic composition, comprising an immunizing amount of the vector of claim 1 and a pharmaceutically or veterinarily acceptable carrier.
10. An immunogenic composition, comprising an immunizing amount of the vector of claim 2 and a pharmaceutically or veterinarily acceptable carrier.
11. An immunogenic composition, comprising an immunizing amount of the vector of claim 3 and a pharmaceutically or veterinarily acceptable carrier.
12. An immunogenic composition, comprising an immunizing amount of the vector of claim 4 and a pharmaceutically or veterinarily acceptable carrier.
13. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 5 .
14. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 6 .
15. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 7 .
16. A method for treating or preventing porcine circovirus type B infection in a mammalian subject, comprising administering to said subject a therapeutically effective amount of a vaccine according to claim 8 .
17. A recombinant polynucleotide comprising a sequence having at least 90% sequence identity to SEQ. ID. NO: 25.
18. A recombinant polynucleotide comprising a sequence having at least 95% sequence identity to SEQ. ID. NO: 25.
19. A method for detecting and quantifying at least one polynucleotide of a porcine circovirus type B (PCVB) by a hybridization method, wherein said polynucleotide comprises a sequence with at least 90% identity to SEQ ID NO: 25.
20. A method for detecting and quantifying at least one polynucleotide of a porcine circovirus type B (PCVB) by a hybridization method, wherein said polynucleotide comprises a sequence with at least 95% identity to SEQ ID NO: 25.
21. A method for expressing ORF′2 of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 1 .
22. A method for expressing ORF′2 of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 2 .
23. The method of claim 22 , wherein the cells are SF9 cells.
24. A method for expressing ORF′2 of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 3 .
25. A method for expressing ORF′2 of a porcine circovirus type B (PCVB) in vitro, comprising transfecting cells in culture with the vector of claim 4 .
26. The method of claim 25 , wherein the cells are SF9 cells.
27. A method for expressing ORF′2 of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 1 to a mammal.
28. The method of claim 27 , wherein the mammal is a pig.
29. A method for expressing ORF′2 of a porcine circovirus type B (PCVB) in vivo, comprising administering the vector of claim 3 to a mammal.
30. The method of claim 29 , wherein the mammal is a pig.